GlaxoSmithKline 'knew about heart attack risks of Avandia,' claim US Senators, who also slam FDA
A US Senate committee has alleged that UK drugs giant GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) poses increased risk of heart attacks, a conclusion which has been rejected by the company, and also criticizes the nation's drug regulatory body.
The 334-page, based on a two-year enquiry of the drug that was and issued on Saturday (February 20) also criticized the US Food and Drug Administration, saying that medications overlooked or overrode safety concerns found by its staff and claimed that GSK is aware of the possible cardiac risks associated with the diabetes drug, which generated sales of £771 million ($1.19 billion, down 16% on 2008, for the drugmaker last year.
Avandia sales already falling away
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze